Objective: To develop a theoretical framework and process to define and identify pharmacist-sensitive outcomes for chronic diseases and propose how these can be operationalized within practice, policy, and research. Methods: A collaborative medication management framework was developed to provide a platform for identifying outcomes sensitive to pharmacists' contribution to patient's care. Potential indicators for specific pharmacist's roles identified were: supporting medication-prescribing practice; medication-taking practice; and medication-related information transfer. Clinical indicators of potential impact on patient's outcomes were noted. The framework was used to structure gathering, selecting, and processing of literature-based information. We searched IPA, Medline, and Embase (inception-2006) to identify research describing the impact of pharmacists' patient-care interventions. Two independent reviewers identified articles, then extracted data; results were compared and settled through consensus. Articles were grouped by disease. Outcomes/indicators were categorized as definitely sensitive, probably sensitive, probably not sensitive, or definitely not pharmacist-sensitive. Data extracted included intervention type, patient numbers, demographics, study characteristics, instruments used, data compared, and outcomes. Where sufficient, data were combined in a random-effects meta-analysis. Study quality was assessed using Downs-Black scale. Results: The framework and the methodology developed are effective in synthesizing and interpreting literature data to identify pharmacist-sensitive outcomes. Average study quality was 62%±11% (“fair”). Significant impacts were found on reducing glycosylated hemoglobin (0.62%±0.29%; N=2247; k=16; P=0.03) and systolic blood pressure (6.9±3.5 mmHg; N=2246; k=13; P=0.047). Non-sensitive were diastolic blood pressure (3.6±1.9 mmHg; N=2246; k=13; P=0.06), quality of life (1/8 significant) and compliance (5/13 significant). Conclusion: Pharmacist-sensitive outcomes identified to date are for diabetes and hypertension (in progress are asthma-COPD, congestive heart failure, mental illnesses and arthritis). More research studies are required to verify the significance of findings. Pharmacist-sensitive outcomes is an underdeveloped concept. Current studies primarily assess clinical outcomes and few measure indicators that are more proximal to a pharmacist intervention.